{"entity":{"type":"insider","cik":"0001660684","url":"/insider/0001660684","json_url":"/insider/0001660684.json","name":"BVF Partners OS Ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":555,"n_filings":141,"first":"2016-01-11","last":"2026-06-26","span_basis":"filed_date"},"name_variants":[{"name":"BVF Partners OS Ltd.","source":"filing","n_filings":141,"first_seen":"2016-01-11","last_seen":"2026-06-26"}],"transactions":[{"id":5761149,"accession":"0000921895-26-001688","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-26-001688","line_url":"/filing/0000921895-26-001688#line-4","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF Partners OS Ltd.; LAMPERT MARK N; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; BVF INC/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":837914.0,"shares_display":"837,914","price_per_share":106.5,"price_display":"106.50","price_state":"stated","total_value":89237841.0,"total_display":"89,237,841.00","total_whole":"89,237,841","shares_owned_after":1960881.0,"shares_owned_after_display":"1,960,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-26","scope":"insider"},{"id":5761148,"accession":"0000921895-26-001688","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-26-001688","line_url":"/filing/0000921895-26-001688#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF Partners OS Ltd.; LAMPERT MARK N; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; BVF INC/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":627597.0,"shares_display":"627,597","price_per_share":106.5,"price_display":"106.50","price_state":"stated","total_value":66839080.5,"total_display":"66,839,080.50","total_whole":"66,839,081","shares_owned_after":1592261.0,"shares_owned_after_display":"1,592,261","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-26","scope":"insider"},{"id":5761147,"accession":"0000921895-26-001688","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-26-001688","line_url":"/filing/0000921895-26-001688#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF Partners OS Ltd.; LAMPERT MARK N; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; BVF INC/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":113289.0,"shares_display":"113,289","price_per_share":106.5,"price_display":"106.50","price_state":"stated","total_value":12065278.5,"total_display":"12,065,278.50","total_whole":"12,065,279","shares_owned_after":240123.0,"shares_owned_after_display":"240,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-26","scope":"insider"},{"id":5761146,"accession":"0000921895-26-001688","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-26-001688","line_url":"/filing/0000921895-26-001688#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF Partners OS Ltd.; LAMPERT MARK N; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; BVF INC/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51858.0,"shares_display":"51,858","price_per_share":106.5,"price_display":"106.50","price_state":"stated","total_value":5522877.0,"total_display":"5,522,877.00","total_whole":"5,522,877","shares_owned_after":78787.0,"shares_owned_after_display":"78,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-26","scope":"insider"},{"id":5991670,"accession":"0000921895-26-000895","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-26-000895","line_url":"/filing/0000921895-26-000895#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; BIOTECHNOLOGY VALUE FUND II LP; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF PARTNERS L P/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1932354.0,"shares_display":"1,932,354","price_per_share":16.79,"price_display":"16.79","price_state":"stated","total_value":32444223.66,"total_display":"32,444,223.66","total_whole":"32,444,224","shares_owned_after":8302735.0,"shares_owned_after_display":"8,302,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-02","scope":"insider"},{"id":5991667,"accession":"0000921895-26-000895","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-26-000895","line_url":"/filing/0000921895-26-000895#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; BIOTECHNOLOGY VALUE FUND II LP; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF PARTNERS L P/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1569116.0,"shares_display":"1,569,116","price_per_share":16.79,"price_display":"16.79","price_state":"stated","total_value":26345457.64,"total_display":"26,345,457.64","total_whole":"26,345,458","shares_owned_after":6599722.0,"shares_owned_after_display":"6,599,722","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-02","scope":"insider"},{"id":5991662,"accession":"0000921895-26-000895","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-26-000895","line_url":"/filing/0000921895-26-000895#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; BIOTECHNOLOGY VALUE FUND II LP; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF PARTNERS L P/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":248530.0,"shares_display":"248,530","price_per_share":16.79,"price_display":"16.79","price_state":"stated","total_value":4172818.7,"total_display":"4,172,818.70","total_whole":"4,172,819","shares_owned_after":1039238.0,"shares_owned_after_display":"1,039,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-02","scope":"insider"},{"id":5067501,"accession":"0000921895-25-002133","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-25-002133","line_url":"/filing/0000921895-25-002133#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"ESSA Pharma Inc.","issuer_ticker":"EPIX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":79.0,"shares_display":"79","price_per_share":1.8779,"price_display":"1.88","price_state":"stated","total_value":148.3541,"total_display":"148.35","total_whole":"148","shares_owned_after":6194145.0,"shares_owned_after_display":"6,194,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-05","filed_date":"2025-08-07","scope":"insider"},{"id":5067498,"accession":"0000921895-25-002133","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-25-002133","line_url":"/filing/0000921895-25-002133#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"ESSA Pharma Inc.","issuer_ticker":"EPIX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":66.0,"shares_display":"66","price_per_share":1.8779,"price_display":"1.88","price_state":"stated","total_value":123.9414,"total_display":"123.94","total_whole":"124","shares_owned_after":4726743.0,"shares_owned_after_display":"4,726,743","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-05","filed_date":"2025-08-07","scope":"insider"},{"id":5067494,"accession":"0000921895-25-002133","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-25-002133","line_url":"/filing/0000921895-25-002133#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"ESSA Pharma Inc.","issuer_ticker":"EPIX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11.0,"shares_display":"11","price_per_share":1.8779,"price_display":"1.88","price_state":"stated","total_value":20.6569,"total_display":"20.66","total_whole":"21","shares_owned_after":560797.0,"shares_owned_after_display":"560,797","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-05","filed_date":"2025-08-07","scope":"insider"},{"id":4058547,"accession":"0000921895-25-001910","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-25-001910","line_url":"/filing/0000921895-25-001910#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":142604.0,"shares_display":"142,604","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":6274576.0,"total_display":"6,274,576.00","total_whole":"6,274,576","shares_owned_after":2798795.0,"shares_owned_after_display":"2,798,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider"},{"id":4058544,"accession":"0000921895-25-001910","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-25-001910","line_url":"/filing/0000921895-25-001910#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":115783.0,"shares_display":"115,783","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":5094452.0,"total_display":"5,094,452.00","total_whole":"5,094,452","shares_owned_after":2219858.0,"shares_owned_after_display":"2,219,858","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider"},{"id":4058543,"accession":"0000921895-25-001910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-25-001910","line_url":"/filing/0000921895-25-001910#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":58780.0,"shares_display":"58,780","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":2586320.0,"total_display":"2,586,320.00","total_whole":"2,586,320","shares_owned_after":353412.0,"shares_owned_after_display":"353,412","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider"},{"id":4747320,"accession":"0000921895-25-001602","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-25-001602","line_url":"/filing/0000921895-25-001602#line-2","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF INC/IL; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":265316.0,"shares_display":"265,316","price_per_share":27.1,"price_display":"27.10","price_state":"stated","total_value":7190063.6,"total_display":"7,190,063.60","total_whole":"7,190,064","shares_owned_after":1267545.0,"shares_owned_after_display":"1,267,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-16","filed_date":"2025-05-20","scope":"insider"},{"id":4747299,"accession":"0000921895-25-001602","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-25-001602","line_url":"/filing/0000921895-25-001602#line-1","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF INC/IL; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":127407.0,"shares_display":"127,407","price_per_share":27.1,"price_display":"27.10","price_state":"stated","total_value":3452729.7,"total_display":"3,452,729.70","total_whole":"3,452,730","shares_owned_after":1322758.0,"shares_owned_after_display":"1,322,758","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-16","filed_date":"2025-05-20","scope":"insider"},{"id":5067450,"accession":"0000921895-25-000177","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-25-000177","line_url":"/filing/0000921895-25-000177#line-4","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":339679.0,"shares_display":"339,679","price_per_share":26.1,"price_display":"26.10","price_state":"stated","total_value":8865621.9,"total_display":"8,865,621.90","total_whole":"8,865,622","shares_owned_after":1450165.0,"shares_owned_after_display":"1,450,165","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-28","scope":"insider"},{"id":5067447,"accession":"0000921895-25-000177","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-25-000177","line_url":"/filing/0000921895-25-000177#line-3","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":149975.0,"shares_display":"149,975","price_per_share":26.1,"price_display":"26.10","price_state":"stated","total_value":3914347.5,"total_display":"3,914,347.50","total_whole":"3,914,348","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-28","scope":"insider"},{"id":5067444,"accession":"0000921895-25-000177","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-25-000177","line_url":"/filing/0000921895-25-000177#line-2","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85776.0,"shares_display":"85,776","price_per_share":26.1,"price_display":"26.10","price_state":"stated","total_value":2238753.6,"total_display":"2,238,753.60","total_whole":"2,238,754","shares_owned_after":1532861.0,"shares_owned_after_display":"1,532,861","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-28","scope":"insider"},{"id":5067438,"accession":"0000921895-25-000177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-25-000177","line_url":"/filing/0000921895-25-000177#line-1","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75287.0,"shares_display":"75,287","price_per_share":26.1,"price_display":"26.10","price_state":"stated","total_value":1964990.7,"total_display":"1,964,990.70","total_whole":"1,964,991","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-28","scope":"insider"},{"id":2817990,"accession":"0000921895-24-002409","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-002409","line_url":"/filing/0000921895-24-002409#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Third Harmonic Bio, Inc.","issuer_ticker":"THRD","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; BVF INC/IL; LAMPERT MARK N; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":538420.0,"shares_display":"538,420","price_per_share":14.3,"price_display":"14.30","price_state":"stated","total_value":7699406.0,"total_display":"7,699,406.00","total_whole":"7,699,406","shares_owned_after":1794218.0,"shares_owned_after_display":"1,794,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-31","scope":"insider"},{"id":2817985,"accession":"0000921895-24-002409","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-24-002409","line_url":"/filing/0000921895-24-002409#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Third Harmonic Bio, Inc.","issuer_ticker":"THRD","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; BVF INC/IL; LAMPERT MARK N; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":396963.0,"shares_display":"396,963","price_per_share":14.3,"price_display":"14.30","price_state":"stated","total_value":5676570.9,"total_display":"5,676,570.90","total_whole":"5,676,571","shares_owned_after":1367257.0,"shares_owned_after_display":"1,367,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-31","scope":"insider"},{"id":2817980,"accession":"0000921895-24-002409","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-24-002409","line_url":"/filing/0000921895-24-002409#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Third Harmonic Bio, Inc.","issuer_ticker":"THRD","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; BVF INC/IL; LAMPERT MARK N; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64617.0,"shares_display":"64,617","price_per_share":14.3,"price_display":"14.30","price_state":"stated","total_value":924023.1,"total_display":"924,023.10","total_whole":"924,023","shares_owned_after":176692.0,"shares_owned_after_display":"176,692","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-31","scope":"insider"},{"id":2233765,"accession":"0000921895-24-002263","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-002263","line_url":"/filing/0000921895-24-002263#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; Biotechnology Value Trading Fund OS LP; BVF PARTNERS L P/IL; LAMPERT MARK N; BVF I GP LLC; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1030589.0,"shares_display":"1,030,589","price_per_share":50.0016,"price_display":"50.00","price_state":"stated","total_value":51531098.9424,"total_display":"51,531,098.94","total_whole":"51,531,099","shares_owned_after":10235089.0,"shares_owned_after_display":"10,235,089","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider"},{"id":2233761,"accession":"0000921895-24-002263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-24-002263","line_url":"/filing/0000921895-24-002263#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; Biotechnology Value Trading Fund OS LP; BVF PARTNERS L P/IL; LAMPERT MARK N; BVF I GP LLC; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":836862.0,"shares_display":"836,862","price_per_share":50.0016,"price_display":"50.00","price_state":"stated","total_value":41844438.9792,"total_display":"41,844,438.98","total_whole":"41,844,439","shares_owned_after":8168838.0,"shares_owned_after_display":"8,168,838","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider"},{"id":2233755,"accession":"0000921895-24-002263","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-24-002263","line_url":"/filing/0000921895-24-002263#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; Biotechnology Value Trading Fund OS LP; BVF PARTNERS L P/IL; LAMPERT MARK N; BVF I GP LLC; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":132549.0,"shares_display":"132,549","price_per_share":50.0016,"price_display":"50.00","price_state":"stated","total_value":6627662.0784,"total_display":"6,627,662.08","total_whole":"6,627,662","shares_owned_after":1287768.0,"shares_owned_after_display":"1,287,768","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider"},{"id":2171041,"accession":"0000921895-24-001131","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1031385.0,"shares_display":"1,031,385","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":3361803.0,"shares_owned_after_display":"3,361,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":2171038,"accession":"0000921895-24-001131","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":821121.0,"shares_display":"821,121","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":2633679.0,"shares_owned_after_display":"2,633,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":2171035,"accession":"0000921895-24-001131","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75431.0,"shares_display":"75,431","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":220460.0,"shares_owned_after_display":"220,460","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":8362082,"accession":"0001193805-23-001635","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-23-001635","line_url":"/filing/0001193805-23-001635#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"POINT Biopharma Global Inc.","issuer_ticker":"PNT","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8974245.0,"shares_display":"8,974,245","price_per_share":12.45,"price_display":"12.45","price_state":"stated","total_value":111729350.25,"total_display":"111,729,350.25","total_whole":"111,729,350","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-20","scope":"insider"},{"id":8362078,"accession":"0001193805-23-001635","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-23-001635","line_url":"/filing/0001193805-23-001635#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"POINT Biopharma Global Inc.","issuer_ticker":"PNT","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7290667.0,"shares_display":"7,290,667","price_per_share":12.45,"price_display":"12.45","price_state":"stated","total_value":90768804.15,"total_display":"90,768,804.15","total_whole":"90,768,804","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-20","scope":"insider"},{"id":8362073,"accession":"0001193805-23-001635","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-23-001635","line_url":"/filing/0001193805-23-001635#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"POINT Biopharma Global Inc.","issuer_ticker":"PNT","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":896366.0,"shares_display":"896,366","price_per_share":12.45,"price_display":"12.45","price_state":"stated","total_value":11159756.7,"total_display":"11,159,756.70","total_whole":"11,159,757","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-20","scope":"insider"},{"id":8187203,"accession":"0000921895-23-002669","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-6","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":153693.0,"shares_display":"153,693","price_per_share":5.3837,"price_display":"5.38","price_state":"stated","total_value":827437.0041,"total_display":"827,437.00","total_whole":"827,437","shares_owned_after":5309432.0,"shares_owned_after_display":"5,309,432","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8187200,"accession":"0000921895-23-002669","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-5","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125909.0,"shares_display":"125,909","price_per_share":5.3837,"price_display":"5.38","price_state":"stated","total_value":677856.2833,"total_display":"677,856.28","total_whole":"677,856","shares_owned_after":4308573.0,"shares_owned_after_display":"4,308,573","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8187194,"accession":"0000921895-23-002669","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-4","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16143.0,"shares_display":"16,143","price_per_share":5.3837,"price_display":"5.38","price_state":"stated","total_value":86909.0691,"total_display":"86,909.07","total_whole":"86,909","shares_owned_after":548938.0,"shares_owned_after_display":"548,938","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8187189,"accession":"0000921895-23-002669","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":493337.0,"shares_display":"493,337","price_per_share":4.9999,"price_display":"5.00","price_state":"stated","total_value":2466635.6663,"total_display":"2,466,635.67","total_whole":"2,466,636","shares_owned_after":5155739.0,"shares_owned_after_display":"5,155,739","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8187181,"accession":"0000921895-23-002669","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":390507.0,"shares_display":"390,507","price_per_share":4.9999,"price_display":"5.00","price_state":"stated","total_value":1952495.9493,"total_display":"1,952,495.95","total_whole":"1,952,496","shares_owned_after":4182664.0,"shares_owned_after_display":"4,182,664","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8187174,"accession":"0000921895-23-002669","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":47712.0,"shares_display":"47,712","price_per_share":4.9999,"price_display":"5.00","price_state":"stated","total_value":238555.2288,"total_display":"238,555.23","total_whole":"238,555","shares_owned_after":532795.0,"shares_owned_after_display":"532,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8102416,"accession":"0000921895-23-002475","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-6","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":103885.0,"shares_display":"103,885","price_per_share":14.0689,"price_display":"14.07","price_state":"stated","total_value":1461547.6765,"total_display":"1,461,547.68","total_whole":"1,461,548","shares_owned_after":2656191.0,"shares_owned_after_display":"2,656,191","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-06","scope":"insider"},{"id":8102413,"accession":"0000921895-23-002475","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-5","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":83708.0,"shares_display":"83,708","price_per_share":14.0689,"price_display":"14.07","price_state":"stated","total_value":1177679.4812,"total_display":"1,177,679.48","total_whole":"1,177,679","shares_owned_after":2104075.0,"shares_owned_after_display":"2,104,075","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-06","scope":"insider"},{"id":8102410,"accession":"0000921895-23-002475","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-4","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10106.0,"shares_display":"10,106","price_per_share":14.0689,"price_display":"14.07","price_state":"stated","total_value":142180.3034,"total_display":"142,180.30","total_whole":"142,180","shares_owned_after":294632.0,"shares_owned_after_display":"294,632","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-06","scope":"insider"},{"id":8102407,"accession":"0000921895-23-002475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":132016.0,"shares_display":"132,016","price_per_share":11.6444,"price_display":"11.64","price_state":"stated","total_value":1537247.1104,"total_display":"1,537,247.11","total_whole":"1,537,247","shares_owned_after":2020367.0,"shares_owned_after_display":"2,020,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-06","scope":"insider"},{"id":8102402,"accession":"0000921895-23-002475","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57618.0,"shares_display":"57,618","price_per_share":11.6444,"price_display":"11.64","price_state":"stated","total_value":670927.0392,"total_display":"670,927.04","total_whole":"670,927","shares_owned_after":2552306.0,"shares_owned_after_display":"2,552,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-06","scope":"insider"},{"id":8102399,"accession":"0000921895-23-002475","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":26772.0,"shares_display":"26,772","price_per_share":11.6444,"price_display":"11.64","price_state":"stated","total_value":311743.8768,"total_display":"311,743.88","total_whole":"311,744","shares_owned_after":284526.0,"shares_owned_after_display":"284,526","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-06","scope":"insider"},{"id":7887682,"accession":"0000921895-23-002458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002458","line_url":"/filing/0000921895-23-002458#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":492251.0,"shares_display":"492,251","price_per_share":3.6,"price_display":"3.60","price_state":"stated","total_value":1772103.6,"total_display":"1,772,103.60","total_whole":"1,772,104","shares_owned_after":3792157.0,"shares_owned_after_display":"3,792,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-03","scope":"insider"},{"id":7887679,"accession":"0000921895-23-002458","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-23-002458","line_url":"/filing/0000921895-23-002458#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":218979.0,"shares_display":"218,979","price_per_share":3.6,"price_display":"3.60","price_state":"stated","total_value":788324.4,"total_display":"788,324.40","total_whole":"788,324","shares_owned_after":4662402.0,"shares_owned_after_display":"4,662,402","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-03","scope":"insider"},{"id":7887675,"accession":"0000921895-23-002458","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-23-002458","line_url":"/filing/0000921895-23-002458#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72479.0,"shares_display":"72,479","price_per_share":3.6,"price_display":"3.60","price_state":"stated","total_value":260924.4,"total_display":"260,924.40","total_whole":"260,924","shares_owned_after":485083.0,"shares_owned_after_display":"485,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-03","scope":"insider"},{"id":8245370,"accession":"0000921895-23-002167","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002167","line_url":"/filing/0000921895-23-002167#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Olema Pharmaceuticals, Inc.","issuer_ticker":"OLMA","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N; BVF I GP LLC; BVF II GP LLC; BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":775278.0,"shares_display":"775,278","price_per_share":9.84,"price_display":"9.84","price_state":"stated","total_value":7628735.52,"total_display":"7,628,735.52","total_whole":"7,628,736","shares_owned_after":4688954.0,"shares_owned_after_display":"4,688,954","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-14","scope":"insider"},{"id":8245366,"accession":"0000921895-23-002167","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-23-002167","line_url":"/filing/0000921895-23-002167#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Olema Pharmaceuticals, Inc.","issuer_ticker":"OLMA","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N; BVF I GP LLC; BVF II GP LLC; BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":677853.0,"shares_display":"677,853","price_per_share":9.84,"price_display":"9.84","price_state":"stated","total_value":6670073.52,"total_display":"6,670,073.52","total_whole":"6,670,074","shares_owned_after":3584512.0,"shares_owned_after_display":"3,584,512","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-14","scope":"insider"},{"id":8245361,"accession":"0000921895-23-002167","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-23-002167","line_url":"/filing/0000921895-23-002167#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Olema Pharmaceuticals, Inc.","issuer_ticker":"OLMA","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N; BVF I GP LLC; BVF II GP LLC; BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":52801.0,"shares_display":"52,801","price_per_share":9.84,"price_display":"9.84","price_state":"stated","total_value":519561.84,"total_display":"519,561.84","total_whole":"519,562","shares_owned_after":524151.0,"shares_owned_after_display":"524,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-14","scope":"insider"},{"id":8063646,"accession":"0000921895-23-001098","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-001098","line_url":"/filing/0000921895-23-001098#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; LAMPERT MARK N; BVF PARTNERS L P/IL; BVF INC/IL","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1055445.0,"shares_display":"1,055,445","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":2330418.0,"shares_owned_after_display":"2,330,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-05","filed_date":"2023-05-09","scope":"insider"}],"next_cursor":"2023-05-05|8063646","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Director, Other","n_filings":11,"first_seen":"2021-07-06","last_seen":"2026-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001821586","name":"MoonLake Immunotherapeutics","url":"/issuer/0001821586","role":"Director, Other","n_filings":2,"first_seen":"2024-10-08","last_seen":"2026-04-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001633932","name":"ESSA Pharma Inc.","url":"/issuer/0001633932","role":"Other","n_filings":1,"first_seen":"2025-08-07","last_seen":"2025-08-07"},{"type":"issuer","type_label":"ISSUER","cik":"0000791908","name":"XOMA Royalty Corp","url":"/issuer/0000791908","role":"Director, Other","n_filings":25,"first_seen":"2018-11-19","last_seen":"2025-05-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001923840","name":"Third Harmonic Bio, Inc.","url":"/issuer/0001923840","role":"Other","n_filings":2,"first_seen":"2022-12-22","last_seen":"2024-10-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001404281","name":"Eledon Pharmaceuticals, Inc.","url":"/issuer/0001404281","role":"Other","n_filings":2,"first_seen":"2023-05-09","last_seen":"2024-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001811764","name":"POINT Biopharma Global Inc.","url":"/issuer/0001811764","role":"Other","n_filings":1,"first_seen":"2023-12-20","last_seen":"2023-12-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001808158","name":"Repare Therapeutics Inc.","url":"/issuer/0001808158","role":"Other","n_filings":6,"first_seen":"2022-01-21","last_seen":"2023-11-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001750284","name":"Olema Pharmaceuticals, Inc.","url":"/issuer/0001750284","role":"Director, Other","n_filings":4,"first_seen":"2020-11-20","last_seen":"2023-09-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001724979","name":"Rain Therapeutics Inc.","url":"/issuer/0001724979","role":"Director, Other","n_filings":9,"first_seen":"2021-05-17","last_seen":"2022-11-10"},{"type":"issuer","type_label":"ISSUER","cik":"0000891293","name":"CTI BIOPHARMA CORP","url":"/issuer/0000891293","role":"Director, Ten percent owner, Other","n_filings":4,"first_seen":"2016-01-11","last_seen":"2022-08-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001789972","name":"Cullinan Oncology, Inc.","url":"/issuer/0001789972","role":"Other","n_filings":3,"first_seen":"2022-04-05","last_seen":"2022-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001651311","name":"Merus N.V.","url":"/issuer/0001651311","role":"Other","n_filings":14,"first_seen":"2020-01-15","last_seen":"2021-10-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001113148","name":"INFINITY PHARMACEUTICALS, INC.","url":"/issuer/0001113148","role":"Ten percent owner, Other","n_filings":13,"first_seen":"2016-12-02","last_seen":"2021-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001676725","name":"IDEAYA Biosciences, Inc.","url":"/issuer/0001676725","role":"Other","n_filings":3,"first_seen":"2020-06-22","last_seen":"2021-02-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001061983","name":"CYTOKINETICS INC","url":"/issuer/0001061983","role":"Other","n_filings":3,"first_seen":"2019-12-12","last_seen":"2020-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001175505","name":"FIVE PRIME THERAPEUTICS, INC.","url":"/issuer/0001175505","role":"Other","n_filings":12,"first_seen":"2019-10-08","last_seen":"2020-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"GLYCOMIMETICS INC","url":"/issuer/0001253689","role":"Other","n_filings":3,"first_seen":"2019-09-09","last_seen":"2020-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001496671","name":"Calithera Biosciences, Inc.","url":"/issuer/0001496671","role":"Other","n_filings":4,"first_seen":"2019-10-31","last_seen":"2020-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001583648","name":"PIERIS PHARMACEUTICALS, INC.","url":"/issuer/0001583648","role":"Other","n_filings":1,"first_seen":"2019-09-10","last_seen":"2019-09-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Other","n_filings":3,"first_seen":"2017-10-23","last_seen":"2019-06-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001437786","name":"IMMUNE DESIGN CORP.","url":"/issuer/0001437786","role":"Other","n_filings":1,"first_seen":"2018-12-04","last_seen":"2018-12-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001019695","name":"ARQULE INC","url":"/issuer/0001019695","role":"Other","n_filings":3,"first_seen":"2018-04-06","last_seen":"2018-06-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001582313","name":"Xenon Pharmaceuticals Inc.","url":"/issuer/0001582313","role":"Other","n_filings":6,"first_seen":"2017-06-08","last_seen":"2017-08-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001626199","name":"Nivalis Therapeutics, Inc.","url":"/issuer/0001626199","role":"Other","n_filings":5,"first_seen":"2017-05-11","last_seen":"2017-06-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001660684","retrieved_at":"2026-08-22T04:52:50+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}